Signal active
Investment Firm
Overview
F-Prime's roots are in one of America’s great entrepreneurial success stories. Fidelity Investments was founded in 1946 and grew from a single mutual fund into one of the largest asset management firms in the world, with over $2 trillion in assets under management. For the last forty years, this venture capital group has had the privilege of backing other great entrepreneurs as they built ground-breaking companies in technology and life sciences, including Atari, MCI, ROLM Corp., Alibaba, Ironwood Pharmaceuticals, and Ultragenyx.
Today, F-Prime's funds are larger and more global, but its teams are still small and local. F-Prime stays true to its entrepreneurial roots. In the US and Europe, F-Prime Capital Partners is investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, its sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai.
Together F-Prime brings a world of insight, domain expertise and relationships to support entrepreneurs. Without the pressure of fundraising from outside investors, F-Prime Capital Partners focuses all of its time finding and helping great entrepreneurs build important companies.
Highlights
1946
Financial Services
11-50
457
115
91
Early Stage Venture, Late Stage Venture, Seed, Private Equity
Venture Capital
Location
United States, North America
Contact Information
Social
Profile Resume
F-Prime Capital, established in 1946 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Seed, Private Equity investments across Biotechnology, Medical, Therapeutics, Financial Services, Venture Capital, Finance, Consumer, Health Care, Manufacturing, Medical Device. The organization boasts a portfolio of 456 investments, with an average round size of $60.4M and 91 successful exits. Their recent investments include Proteostasis Therapeutics, New Enterprise Associates, HealthCare Ventures, Novartis Venture Fund, Sanofi Ventures. The highest investment round they participated in was $2158.1B. Among their most notable exits are Proteostasis Therapeutics and New Enterprise Associates. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
457
84
115
91
Investments
457
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Jun 27, 2024 | Odaseva | Enterprise Software | 54.0M |
Jun 27, 2024 | RareCyte | Biotechnology | 20.0M |
Jul 09, 2024 | Canoe | FinTech | 36.0M |
Jul 25, 2024 | - | - | 4.0M |
Exits
91
Funding Timeline
457
0
0
Funding Rounds
457
F-Prime Capital has raised 457 rounds. Their latest funding was raised on Jul 25, 2024 from a Seed Round - Kintsu round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Jun 27, 2024 | Series C - Odaseva | - | 54.0M | - |
Jun 27, 2024 | Venture Round - RareCyte | - | 20.0M | - |
Jul 09, 2024 | Series C - Canoe | - | 36.0M | - |
Jul 25, 2024 | Seed Round - Kintsu | - | 4.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.